Sector: Life Sciences

Latest content

The fast-evolving cannabis patent dispute landscape

GW’s recent ANDA lawsuit is a landmark moment, but will remain untypical of cannabis IP litigation

06 February 2023

Novartis wins German injunction following string of European Gilenya litigation defeats

The Dusselfdorf Regional Court has issued a sales ban against eight generics in the much-watched dispute

03 February 2023

Neglect begets opportunity in femtech IP

Femtech entrepreneurs can take advantage of large empty spaces on the patent landscape to secure IP protection for their innovations

02 February 2023

New US trade secrets law a ‘potential sledgehammer’ in dispute negotiations

President can now pick out foreign entities and subject them to a series of sanctions

01 February 2023

English High Court backs Oxford University in landmark tech transfer IP ruling

OUI’s patent policies were not unfair to spinout co-founder under consumer protection laws

31 January 2023

Ten things to know about the controversial Humira patent saga

With Amgen’s biosimilar finally set to launch in the US, IAM looks back on arguably the most interesting set of pharma patent disputes in recent years

30 January 2023

Bristol-Myers Squibb seeks further immuno-oncology patent revenues with AstraZeneca suit

The company has already secured lucrative settlements with Merck and Roche

26 January 2023

New head of Mexican IP office begins work amid IP community concerns

Director General José Sánchez Pérez meets with local lawyers to discuss enforcement and implementation of IP law

25 January 2023

We are willing to litigate our CRISPR patents, says IP chief on the CVC side

ERS Genomics’ Michael Arciero shares his views on the Cas9 licensing landscape in an exclusive IAM interview

24 January 2023

Despite Teva’s English court of appeal defeat, Arrow declarations remain a valuable weapon for generics

The judgment is one of only a few decisions addressing the pre-emptive litigation defence

19 January 2023

• <
• 1
• ...
• 2
• 3
• ...
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• ...
• >